Acute Heart Failure - Pipeline Assessment and Market Forecasts to 2017

Acute Heart Failure - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Heart Failure - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Heart Failure market. The report identifies the key trends shaping and driving the global Acute Heart Failure market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Heart Failure sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates the acute heart failure (AHF) therapeutics market to be valued at $2.6 billion in 2009. The market is estimated to grow up to $3.2 billion in 2017, with a CAGR of 2.5%. Growth in the AHF market will be driven by the increasing number of patients. New drugs might not impact the annual cost of therapy as most of the AHF patients continue their treatment after hospitalization. The US is the largest market for AHF and it contributes to approximately 45% of the global market.

Scope

The report provides information on the key drivers and challenges of the Acute Heart Failure market. Its scope includes:

• Annualized global Acute Heart Failure market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Vasopressin V2 receptor antagonist, Renin Inhibitor, Loop Diuretic, NPR-B Agonist ,SGC Activator, cGMP-activator, Na+/K+ ATPase Inhibitor.
• Analysis of the current and future competition in the global Acute Heart Failure market. Key market players covered are Biogen Idec, Novartis, Nile Therapeutics, Bayer AG, Cardioxyl Pharma, Pharis biotech, Debiopharm.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Heart Failure therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Acute Heart Failure market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Heart Failure market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Acute Heart Failure market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 ACUTE HEART FAILURE: DISEASE OVERVIEW

2.1 Overview
  2.1.1 Etiology
  2.1.2 Clinical Classification
  2.1.3 Prognosis
2.2 Diagnosis
  2.2.1 Initial Evaluation
  2.2.2 Diagnostic Tests
2.3 Management of Acute Heart Failure
2.4 GlobalData Pipeline Report Guidance

3 ACUTE HEART FAILURE: MARKET CHARACTERIZATION

3.1 Overview
3.2 Acute Heart Failure Market Size
3.3 Acute Heart Failure Market Forecast and CAGR
3.4 Drivers and Barriers for the AHF Market
  3.4.1 Drivers of the Acute Heart Failure Market
  3.4.2 Barriers for the Acute Heart Failure Market

4 OPPORTUNITY AND UNMET NEED

4.1 Key Takeaway

5 ACUTE HEART FAILURE MARKET: COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile for the Major Marketed Products in the Acute Heart Failure Market
  5.3.1 Natrecor (Nesiritide)
  5.3.2 Primacor (Milrinone Lactate)
  5.3.3 Coreg (Carvedilol)
  5.3.4 Altace (Ramipril)
  5.3.5 Atacand (Candesartan)
5.4 Key Takeaway

6 ACUTE HEART FAILURE: PIPELINE ASSESSMENT

6.1 Overview
6.2 Strategic Pipeline Assessment
  6.2.1 Technology Trends Analytic Framework
6.3 Acute Heart Failure Therapeutics – Promising Drugs under Clinical Development
6.4 Drugs under Clinical Development
  6.4.1 Tekturna/Rasilez
  6.4.2 Lixivaptan
  6.4.3 Relaxin
  6.4.4 Cinaciguat
6.5 Acute Heart Failure Therapeutics – Pipeline by Mechanism of Action
6.6 Acute Heart Failure Pipeline – Pipeline by Clinical Phases of Development
  6.6.1 Acute Heart Failure Therapeutics – Phase III Clinical Pipeline
  6.6.2 Acute Heart Failure Therapeutics – Phase II Clinical Pipeline
6.7 Key Takeaway

7 ACUTE HEART FAILURE MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

8 ACUTE HEART FAILURE MARKET: FUTURE PLAYERS IN THE ACUTE HEART FAILURE MARKET

8.1 Introduction
8.2 Novartis AG
  8.2.1 Overview
  8.2.2 Business Description
  8.2.3 Cardiovascular Portfolio
  8.2.4 Acute Heart Failure Product Portfolio
8.3 Biogen Idec.
  8.3.1 Overview
  8.3.2 Business Description
  8.3.3 Cardiovascular Portfolio
  8.3.4 Acute Heart Failure Product Portfolio
8.4 Bayer AG
  8.4.1 Overview
  8.4.2 Business Description
  8.4.3 Cardiovascular Portfolio
  8.4.4 Acute Heart Failure Product Portfolio

9 ACUTE HEART FAILURE MARKET: APPENDIX

9.1 Definitions
9.2 Abbreviations
9.3 Research Methodology
  9.3.1 Coverage
  9.3.2 Secondary Research
  9.3.3 Forecasting
  9.3.4 Primary Research
  9.3.5 Expert Panels
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

LIST OF TABLES

Table 1: Causes and Precipitating Factors of Acute Heart Failure
Table 2: Drugs for the Treatment of AHF, 2010
Table 3: AHF Therapeutics Market, Global, Revenues ($m), 2001-2009
Table 4: AHF Therapeutics Market, Global , Revenue Forecasts ($m), 2009-2017
Table 5: Major Marketed Product in the Acute Heart Failure Market, 2010
Table 6: Acute Heart Failure Therapeutics – Promising Drugs Under Clinical Development, 2010
Table 7: Acute Heart Failure Therapeutics – Phase III Clinical Pipeline, 2010
Table 8: Acute Heart Failure Therapeutics – Phase II Clinical Pipeline, 2010
Table 9: Novartis AG – Cardiovascular and Acute Heart Failure Pipeline, 2010
Table 10: Biogen Idec. – Cardiovascular and Acute Heart Failure Pipeline, 2010
Table 11: Bayer AG – Cardiovascular and Acute Heart Failure Pipeline, 2010

LIST OF FIGURES

Figure 1: Clinical classification of acute heart failure
Figure 2: Evaluation of Patients with Suspected AHF
Figure 3: AHF Therapeutics Market, Global, Revenue ($ billion), 2001–2009
Figure 4: AHF Therapeutics Market, Global, Revenue Forecast ($ billion), 2009-2017
Figure 5: Opportunity and Unmet Need in the AHF Market
Figure 6: Strategic Competitor Assessment of the Major Marketed Products in Acute Heart Failure, 2010
Figure 7: Technology Trends Analytic Framework of the Acute Heart Failure Pipeline, 2010
Figure 8: Technology Trends Analytic Framework of Acute Heart Failure Pipeline – Description, 2010
Figure 9: Acute Heart Failure Therapeutics – Pipeline by Mechanism of Action, 2010
Figure 10: Acute Heart Failure Pipeline by Phase of Clinical Development, 2010
Figure 11: Implications for Future Market Competition in the Acute Heart Failure Market, 2010
Figure 12: Acute Heart Failure Therapeutics Market – Clinical Pipeline by Company, 2010
Figure 13: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Novartis AG
Biogen Idec
Bayer AG Skip to top